Hemopoietic recovery after transplantation
. | Hematocrit, % . | . | . | Total white cell count, × 109/L (mean absolute neutrophil count, × 109/L) . | . | . | Platelets, × 109/L . | . | . | % donor engraftment . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group . | D + 8 . | D + 10 . | D + 12 . | D + 8 . | D + 10 . | D + 12 . | D + 8 . | D + 10 . | D + 12 . | D + 8 . | ||||||
| Irradiation control | 41.9 ± 1.1 | NA | NA | 0.14 ± 0.02 (<0.1) | NA | NA | 17 ± 2 | NA | NA | <0.1 | ||||||
| Control allogeneic | 34.7 ± 1.5 | 40.3 ± 0.8 | NA | 0.54 ± 0.11* (0.26) | 0.68 ± 0.04 (0.41) | NA | 9 ± 2* | 32 ± 2 | NA | 99.7 ± 0.08 | ||||||
| G-CSF allogeneic | 39.4 ± 0.9 | 42.1 ± 1.4 | 39.2 ± 1.6 | 0.53 ± 0.01* (0.23) | 0.81 ± 0.05 (0.34) | 1.03 ± 0.09 (0.64) | 24 ± 7 | 44 ± 3 | 53 ± 4 | 99.8 ± 0.05 | ||||||
| Peg-G-CSF | ||||||||||||||||
| allogeneic | 41.7 ± 0.8 | ND | 39.6 ± 1.1 | 3.05 ± 0.27* (2.2) | ND | 2.13 ± 0.05 (0.93) | 110 ± 13* | ND | 246 ± 46 | >99.9 | ||||||
| Control syngeneic | 40.6 ± 0.9 | 43.8 ± 0.6 | 39.4 ± 1.7 | 0.32 ± 0.05* (0.24) | 0.71 ± 0.08 (0.48) | 0.95 ± 0.11 (0.68) | 33 ± 6* | 38 ± 5 | 53 ± 9 | NA | ||||||
| Control allogeneic | ||||||||||||||||
| TCD | 41.5 ± 0.6 | ND | ND | 0.33 ± 0.03* (0.15) | ND | ND | 33 ± 5* | ND | ND | >99.9 | ||||||
. | Hematocrit, % . | . | . | Total white cell count, × 109/L (mean absolute neutrophil count, × 109/L) . | . | . | Platelets, × 109/L . | . | . | % donor engraftment . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group . | D + 8 . | D + 10 . | D + 12 . | D + 8 . | D + 10 . | D + 12 . | D + 8 . | D + 10 . | D + 12 . | D + 8 . | ||||||
| Irradiation control | 41.9 ± 1.1 | NA | NA | 0.14 ± 0.02 (<0.1) | NA | NA | 17 ± 2 | NA | NA | <0.1 | ||||||
| Control allogeneic | 34.7 ± 1.5 | 40.3 ± 0.8 | NA | 0.54 ± 0.11* (0.26) | 0.68 ± 0.04 (0.41) | NA | 9 ± 2* | 32 ± 2 | NA | 99.7 ± 0.08 | ||||||
| G-CSF allogeneic | 39.4 ± 0.9 | 42.1 ± 1.4 | 39.2 ± 1.6 | 0.53 ± 0.01* (0.23) | 0.81 ± 0.05 (0.34) | 1.03 ± 0.09 (0.64) | 24 ± 7 | 44 ± 3 | 53 ± 4 | 99.8 ± 0.05 | ||||||
| Peg-G-CSF | ||||||||||||||||
| allogeneic | 41.7 ± 0.8 | ND | 39.6 ± 1.1 | 3.05 ± 0.27* (2.2) | ND | 2.13 ± 0.05 (0.93) | 110 ± 13* | ND | 246 ± 46 | >99.9 | ||||||
| Control syngeneic | 40.6 ± 0.9 | 43.8 ± 0.6 | 39.4 ± 1.7 | 0.32 ± 0.05* (0.24) | 0.71 ± 0.08 (0.48) | 0.95 ± 0.11 (0.68) | 33 ± 6* | 38 ± 5 | 53 ± 9 | NA | ||||||
| Control allogeneic | ||||||||||||||||
| TCD | 41.5 ± 0.6 | ND | ND | 0.33 ± 0.03* (0.15) | ND | ND | 33 ± 5* | ND | ND | >99.9 | ||||||
B6D2F1 irradiation control animals (n = 4) received 1100 cGy total body irradiation, as described in “Materials and methods,” but did not receive a transplant inoculum. Control allogeneic animals (n = 8), G-CSF allogeneic animals (n = 8), peg-G-CSF animals (n = 8), and control syngeneic animals (n = 4) received splenocytes from CD45.1+ B6 donors pretreated with control diluent or cytokine as indicated and as described in “Materials and methods.” Control allogeneic T-cell—depleted (TCD) animals (n = 4) received TCD spleen from control pretreated donors. Blood was collected on days 8, 10, and 12 after transplantation, as shown and analyzed as described in “Materials and methods.” Data are presented as mean ± SEM. *P < .05 versus irradiation control. All values are mean ± SEM. NA indicates not assessable; ND, not determined.